
Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients
Summary
Alpha Tau Medical shared positive interim results from a United States clinical trial evaluating Alpha DaRT therapy for recurrent glioblastoma. Data from the ongoing study show complete tumor clearance in all six evaluable patients who reached the MRI response assessment stage.
Alpha Tau Medical Ltd. (NASDAQ:DRTS) on Sunday reported positive interim results from its U.S. REGAIN trial evaluating Alpha DaRT therapy in patients with recurrent glioblastoma.The data capture patient outcomes through November 11, 2026.Strong Tumor Response RatesClinicians have treated eight patients in the trial so far, and six have reached MRI response assessment. Under RANO criteria, all six evaluable patients achieved…
Source: Read the full story at Top Stories Feed